Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipation Treatment Market Driver

What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain effective pain management without the discomfort of constipation. The Government of Canada estimated that 8.3 million Canadians could experience chronic pain by 2025, growing to 9 million by 2030. This increasing use of opioids is pushing the growth of the OIC treatment market.

Get Your Opioid-Induced Constipation Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/opioid-induced-constipation-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the opioid-induced constipation treatment market from 2025 to 2034, and what factors influence it?
The opioid-induced constipation (OIC) treatment market has grown strongly, increasing from $1.78 billion in 2024 to $1.9 billion in 2025 at a CAGR of 7.0%. Growth drivers include an expanding geriatric population, personalized OIC treatments, availability of effective drugs, rising opioid use, and an increasing prevalence of gastrointestinal disorders.

The Opioid-Induced Constipation Treatment Market is projected to hit $2.47 billion by 2029, at a CAGR of 6.7%. Growth is driven by increasing opioid prescriptions and R&D investments. Trends include targeted therapies, biotech innovations, and non-pharmacological interventions.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15881&type=smp

How are the latest trends influencing the growth of the opioid-induced constipation treatment market?
In the opioid-induced constipation treatment market, companies are adopting strategic partnerships to develop innovative medicines. These collaborations enhance research capabilities and accelerate the commercialization of new treatments. For example, in November 2022, Kyowa Kirin Co. Ltd. partnered with Grünenthal GmbH to develop treatments for opioid-induced constipation, as well as other pain management conditions.

What are the major segments of the opioid-induced constipation treatment market and their role in driving growth?
The opioid-induced constipation treatment market covered in this report is segmented -

1) By Drug Class: Laxatives, Peripherally Acting μ-opioid Receptor Antagonists, Serotonin Receptor Agonists, Prostaglandin
2) By Type: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:
1) By Laxatives: Osmotic Laxatives, Stimulant Laxatives, Bulk-Forming Laxatives
2) By Peripherally Acting μ-Opioid Receptor Antagonists: Naloxegol, Methylnaltrexone, Alvimopan
3) By Serotonin Receptor Agonists: Prucalopride, Tegaserod
4) By Prostaglandin: Lubiprostone

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15881

Which geographical regions are pioneering growth in the opioid-induced constipation treatment market?
North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the opioid-induced constipation treatment market?
Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15881&type=smp

What Is Covered In The Opioid-Induced Constipation Treatment Global Market Report?

•Market Size Forecast: Examine the opioid-induced constipation treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the opioid-induced constipation treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the opioid-induced constipation treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the opioid-induced constipation treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the opioid-induced constipation treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the opioid-induced constipation treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the opioid-induced constipation treatment market.
•Competitive Landscape: Review strategic developments in the opioid-induced constipation treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.